Wanbang - Jan 21, 2010
China’s largest insulin producer Wangbang Biopharma assigned the Heidelberg, Germany based i+o Industrieplanung + Organisation with the general planning of a facility for production, filling and packaging of insulin products. With state-of-the-art technology the insulin facility will produce during the first building stage about 130 Mio units per year, predominantly for exporting to Europe and the USA. In the process the i+o planning team is facing the special challenge that the complete production process needs to adhere to international GMP requirements.